Cellectis (CLLS) EPS (Weighted Average and Diluted) (2015 - 2025)
Cellectis (CLLS) posted EPS (Weighted Average and Diluted) of -$1.08 for Q4 2025, down 73.24% on a QoQ basis from -$0.62 in Q4 2024, and down 73.24% year-over-year from -$4.03 in Q4 2024.
Cellectis (CLLS) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.08 in Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) fell 73.24% year-over-year to -$1.08; the TTM figure through Dec 2025 stood at -$1.08 (down 73.24% YoY), while the FY2025 annual figure was -$0.67, down 63.41% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$1.08 in Q4 2025, from -$0.62 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.06 in Q4 2022 and bottomed at -$1.08 in Q4 2025.
- A 5-year average of -$0.46 and a median of -$0.41 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) jumped 51.0% — and 2023, when it slumped 970.06%.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.13 in 2021, then jumped by 51.0% to -$0.06 in 2022, then slumped by 970.06% to -$0.68 in 2023, then advanced by 8.51% to -$0.62 in 2024, then plunged by 73.24% to -$1.08 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.08 (Q4 2025), -$0.62 (Q4 2024), and -$0.68 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 |
| Dec 31, 2024 | -0.62 |
| Dec 31, 2023 | -0.68 |
| Jun 30, 2023 | -0.20 |
| Dec 31, 2022 | -0.06 |
| Dec 31, 2021 | -0.18 |
| Mar 31, 2015 | -15,469.57 |